UCon Treatment of Overactive Bladder (OAB) in Males

September 30, 2025 updated by: InnoCon Medical

Safety and Performance of UCon for Management of Non-Neurogenic OAB in Males - An Early Feasibility Study

UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The purpose of the current investigation is to obtain information about the type of stimulation that Ucon provide (time limited vs. urge stimulation), would be the most effective and feasible for the treatment of non-neurogenic OAB symptoms in males.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Netherlands
      • Maastricht, Netherlands
        • Recruiting
        • Maastricht University Medical Center+
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Subject is ≥ 18 years of age.
  2. Subject is male.
  3. Subject is diagnosed with OAB
  4. Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation.

Exclusion Criteria:

  1. Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation).
  2. Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)).
  3. Subject has an active infection in the genital area incl. skin infections and urinary tract infection.
  4. Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months.
  5. Subject has used antimuscarinics or β3 agonists within 14 days weeks*.
  6. Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).
  7. Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment.
  8. Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.
  9. Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region.
  10. Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.

  11. Subject does not speak and understand Dutch.

    • If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Group A (Urge and Time limited)
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 60 seconds by the participant when he experience urgency (urge stimulation).The urge stimulation can be activated repeatedly during the day as the participant wears the device from morning to evening at home for 14 days. Following a stimulation wash-out period (14 days), the participants then stimulates with UCon for another 14 days using the time limited stimulation mode.
Device: Urge stimulation
Participants will receive stimulation for 60 seconds, when they feel an urgency.
Other Names:
  • Neurostimulation
  • DGN stimulation
Device: Time limited stimulation
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Other Names:
  • Neurostimulation
  • DGN stimulation
Other: Group B (Time limited and Urge)
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 30 minutes once a day, at a time that is convenient for the participant. The participant uses the device at home for 14 days. Following a stimulation wash-out period (14 days), the participant then stimulates with UCon for another 14 days using the urge stimulation mode.
Device: Urge stimulation
Participants will receive stimulation for 60 seconds, when they feel an urgency.
Other Names:
  • Neurostimulation
  • DGN stimulation
Device: Time limited stimulation
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Other Names:
  • Neurostimulation
  • DGN stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PRIMARY SAFETY: To evaluate adverse events [initial safety] of UCon for treatment of OAB symptoms in a home setting.
Time Frame: After 44 days (end of study)
Characterization of adverse events and anticipated adverse device effects associated with the use of UCon during the investigational period.
After 44 days (end of study)
PRIMARY PERFORMANCE: To evaluate the ratio of treatment change [performance] of OAB symptoms using UCon in a home setting
Time Frame: Change from baseline at 14 days, 30 days and 44 days (study end)

Ratio of subjects with at least 50% change in their OAB symptoms from baseline. Participants shall complete a 3-day bladder diary to report their symptoms.

The symptoms related to OAB:

  • Urinary urgency is measured by number of urgency episodes/day.
  • Urinary frequency is measured by number of voidings/day.
  • Urgency urinary incontinence is measured by number of leaks preceded by urgency/day.
  • Nocturia is measured by number of voidings/night.
Change from baseline at 14 days, 30 days and 44 days (study end)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SECONDARY SAFETY: To identify the number of subjects experiencing adverse events associated with the use of UCon during the investigational period.
Time Frame: After 44 days (end of study)
Number of subjects experiencing adverse events and anticipated adverse device effects. Subjects will report on any experience associated with the use of UCon.
After 44 days (end of study)
SECONDARY SAFETY: To evaluate the severity of adverse events associated with the use of UCon during the investigational period.
Time Frame: After 44 days (study end)
Severity of adverse events and anticipated adverse device effects.The severity will be evaluated from the subjects' report on any experience associated with the use of UCon.
After 44 days (study end)
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their quality of life.
Time Frame: Change from baseline at 14 days and 44 days (end of study)
Ratio of subjects with a change in their OAB quality of life measures as assessed by specific QoL questionnaires related to OAB condition (ICIQ-OAB, AOBq). An overall score with greater values indicates a worse symptom outcome.
Change from baseline at 14 days and 44 days (end of study)
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their treatment outcome (i.e. symptoms) after therapy.
Time Frame: Change from baseline at 14 days and 44 days (end of study)
Ratio of subjects with a change in their treatment outcome (i.e. symptoms) assessed by the 7-point Patient Global Impression of Improvement (PGI-I) scale. Higher scores indicates a worse treatment outcome.
Change from baseline at 14 days and 44 days (end of study)
SECONDARY PERFORMANCE: To evaluate the device and treatment acceptability of UCon.
Time Frame: After 44 days (study end)
Ratio of subjects that accept UCon and DGN stimulation as assessed by a satisfaction survey recorded after each stimulation period.
After 44 days (study end)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

InnoCon Medical

Investigators

  • Principal Investigator: John Heesakkers, MD, Maastricht UMC+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 12, 2023

Primary Completion (Estimated)

June 12, 2026

Study Completion (Estimated)

June 12, 2026

Study Registration Dates

First Submitted

May 1, 2023

First Submitted That Met QC Criteria

May 23, 2023

First Posted (Actual)

May 24, 2023

Study Record Updates

Last Update Posted (Estimated)

October 1, 2025

Last Update Submitted That Met QC Criteria

September 30, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NL_FEAS_01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Incontinence

Clinical Trials on Urge stimulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe